Cargando…

Population pharmacokinetic analysis of tepotinib, an oral MET kinase inhibitor, including data from the VISION study

PURPOSE: Tepotinib is a highly selective, potent, mesenchymal–epithelial transition factor (MET) inhibitor, approved for the treatment of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping. Objectives of this population pharmacokinetic (PK) analysis were to evaluate the dose–exposure...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiong, Wenyuan, Papasouliotis, Orestis, Jonsson, E. Niclas, Strotmann, Rainer, Girard, Pascal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9054876/ https://www.ncbi.nlm.nih.gov/pubmed/35385993 http://dx.doi.org/10.1007/s00280-022-04423-5

Ejemplares similares

Exposure–response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations
por: Xiong, Wenyuan, et al.
Publicado: (2022)

Translational pharmacokinetic‐pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose
por: Xiong, Wenyuan, et al.
Publicado: (2021)

Assessment of the potential of the MET inhibitor tepotinib to affect the pharmacokinetics of CYP3A4 and P-gp substrates
por: Yalkinoglu, Özkan, et al.
Publicado: (2023)

Population pharmacokinetic and pharmacodynamic modeling of evobrutinib in healthy adult participants
por: Papasouliotis, Orestis, et al.
Publicado: (2022)

Biophysical and structural characterization of the impacts of MET phosphorylation on tepotinib binding
por: Grädler, Ulrich, et al.
Publicado: (2023)

The Preclinical Pharmacology of Tepotinib—A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations
por: Albers, Joachim, et al.
Publicado: (2023)

Phase I trial of the MET inhibitor tepotinib in Japanese patients with solid tumors
por: Shitara, Kohei, et al.
Publicado: (2020)

TRLS-03. Intracranial activity of tepotinib in patients with MET exon 14 (METex14) skipping NSCLC enrolled in VISION
por: Bestvina, Christine M, et al.
Publicado: (2021)

SYST-06 INTRACRANIAL ACTIVITY OF TEPOTINIB IN PATIENTS WITH MET EXON 14 (METEX14) SKIPPING NSCLC ENROLLED IN VISION
por: Leighl, Natasha, et al.
Publicado: (2022)

Population pharmacokinetics of atacicept in systemic lupus erythematosus: An analysis of three clinical trials
por: Pitsiu, Maria, et al.
Publicado: (2023)

Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study
por: Sakai, Hiroshi, et al.
Publicado: (2021)

SHP2 Inhibition Influences Therapeutic Response to Tepotinib in Tumors with MET Alterations
por: Pudelko, Linda, et al.
Publicado: (2020)

Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management
por: Veillon, Remi, et al.
Publicado: (2022)

Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B
por: Le, Xiuning, et al.
Publicado: (2023)

Activity and bioavailability of tepotinib for leptomeningeal metastasis of NSCLC with MET exon 14 skipping mutation
por: Tanaka, Hisashi, et al.
Publicado: (2021)

Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice
por: Le, Xiuning, et al.
Publicado: (2022)

MET inhibitor tepotinib antagonizes multidrug resistance mediated by ABCG2 transporter: In vitro and in vivo study
por: Wu, Zhuo-Xun, et al.
Publicado: (2022)

A case of successful desensitization treatment with tepotinib after tepotinib-induced rash
por: Tamura, Tomoki, et al.
Publicado: (2023)

Matching-Adjusted Indirect Comparison (MAIC) of Tepotinib with Other MET Inhibitors for the Treatment of Advanced NSCLC with MET Exon 14 Skipping Mutations
por: Paik, Paul K., et al.
Publicado: (2022)

Tepotinib for advanced non-small-cell lung cancer with MET exon 14 skipping mutations
por: Błaszkowska, M., et al.
Publicado: (2022)

Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression
por: Decaens, Thomas, et al.
Publicado: (2021)

Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation
por: Brazel, Danielle, et al.
Publicado: (2022)

Determination of a clinically effective evobrutinib dose: Exposure–response analyses of a phase II relapsing multiple sclerosis study
por: Papasouliotis, Orestis, et al.
Publicado: (2022)

Design, Synthesis and Antitumor Activity of Novel Selenium-Containing Tepotinib Derivatives as Dual Inhibitors of c-Met and TrxR
por: Hu, Jinhui, et al.
Publicado: (2023)

Open-label, single-center, phase I trial to investigate the mass balance and absolute bioavailability of the highly selective oral MET inhibitor tepotinib in healthy volunteers
por: Johne, Andreas, et al.
Publicado: (2020)

Dramatic intracranial response to tepotinib in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutation
por: Takamori, Shinkichi, et al.
Publicado: (2021)

Correction: Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression
por: Decaens, Thomas, et al.
Publicado: (2021)

Tepotinib Treatment in Patients With MET Exon 14–Skipping Non–Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial
por: Mazieres, Julien, et al.
Publicado: (2023)

Responses to the Tepotinib in Gastric Cancers with MET Amplification or MET Exon 14 Skipping Mutations and High Expression of Both PD-L1 and CD44
por: Sohn, Sung-Hwa, et al.
Publicado: (2022)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Atacicept in a Randomized Trial in Healthy Caucasian and Japanese Subjects
por: Willen, Daniela, et al.
Publicado: (2019)

Pseudo-acute kidney injury secondary to tepotinib
por: Wijtvliet, Veerle, et al.
Publicado: (2022)

Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression
por: Ryoo, Baek-Yeol, et al.
Publicado: (2021)

Lazarus Response to Tepotinib for Leptomeningeal Metastases in a Patient With MET Exon 14 Skipping Mutation–Positive Lung Adenocarcinoma: Case Report
por: Ninomaru, Taira, et al.
Publicado: (2021)

Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation
por: Fujino, Toshio, et al.
Publicado: (2022)

Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis
por: Liam, Chong Kin, et al.
Publicado: (2023)

Tepotinib suppresses proliferation, invasion, migration, and promotes apoptosis of melanoma cells via inhibiting MET and PI3K/AKT signaling pathways
por: Jing, Guifang, et al.
Publicado: (2022)

Capmatinib successfully overcomes tepotinib‐induced intolerable peripheral edema
por: Kunimasa, Kei, et al.
Publicado: (2021)

Successful and Prompt Treatment with Tepotinib for Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Combined with Lung Abscess Formation: A Case Report
por: Makimoto, Go, et al.
Publicado: (2022)

Synthesis, Evaluation, and Mechanism Study of New Tepotinib Derivatives as Antiproliferative Agents
por: Zhang, Niu-niu, et al.
Publicado: (2019)

First-line tepotinib for a very elderly patient with metastatic NSCLC harboring MET exon 14 skipping mutation and high PD-L1 expression
por: Inno, Alessandro, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_prpp3bv6p7dhi9qh7rk32qsvlc